All In Biotech

Drug Trial Radar · NCT06512428

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

An Open-label, Multicenter Phase II Clinical Trial to Explore the Safety and Efficacy of Simmitinib Plus Irinotecan Liposome in Patients With Advanced Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

138

Planned (sponsor's estimate)

Start

Mar 15, 2024

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

  • simmitinib plus irinotecan liposomeDrug

    simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks

  • irinotecan liposomeDrug

    irinotecan liposome 70 mg/m\^2 every 2 weeks

  • irinotecanDrug

    irinotecan 180mg/m\^2 every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase: DLTTime frame: From Cycle 1 Day 1 to Cycle 1 Day 28 (each cycle is 28 days)
  2. Dose Escalation Phase: AETime frame: From first dose to 30 days post the last dose
  3. Randomized controlled study phase: ORRTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Heilongjiang, Harbin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.